抗凝治疗与肺动脉高压生存率的关联:注册登记报告与更新荟萃分析
基于法国国家肺动脉高压注册登记中2009至2020年诊断的1597例PAH患者,380例在诊断时接受抗凝治疗。倾向评分分析显示抗凝与未抗凝患者中位生存期分别为5.62年与5.37年(HR 0.997,95%CI 0.84-1.18,P=0.97)。更新荟萃分析同样未发现抗凝与总体生存显著相关。
要点
- 法国注册登记中抗凝治疗与PAH患者总体生存无显著关联。
- 更新荟萃分析在总体PAH及预设亚组中均未显示抗凝生存获益。
- 抗凝在PAH中的治疗价值仍需随机对照试验证实。
核心结论
- 在全国性注册登记中,PAH患者使用抗凝治疗与总体生存无关。
- 更新荟萃分析结果支持上述发现。
研究设计与样本
- 基于法国国家肺动脉高压注册登记的倾向评分分析,纳入2009至2020年诊断的1597例PAH患者。
- 将注册登记 findings 纳入更新荟萃分析,汇总全国性数据集。
主要发现
- 1597例PAH患者中380例在诊断时接受抗凝治疗。
- 抗凝组中位生存5.62年(95%CI 4.76-6.58),未抗凝组5.37年(95%CI 4.96-5.82),HR 0.997(95%CI 0.84-1.18),log-rank P=0.97。
- 注册登记内所有PAH亚组结果一致。
- 更新荟萃分析总体PAH人群HR 0.98(95%CI 0.78-1.23)。
- 特发性/遗传性PAH或厌食剂相关PAH亚组HR 0.99(95%CI 0.79-1.25),结缔组织病相关PAH亚组HR 0.86(95%CI 0.52-1.42)。
临床怎么用
- 当前证据不支持将抗凝治疗作为PAH患者改善生存的常规策略。
- 抗凝决策需个体化权衡,等待随机对照试验进一步明确治疗价值。
局限性
- 注册登记为观察性设计,存在混杂可能。
- 抗凝治疗的价值需随机对照试验证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of anticoagulant therapy in the management of pulmonary arterial hypertension (PAH) remains uncertain, as existing epidemiologic studies have produced conflicting results. OBJECTIVES: The goal of this study was to examine the association between anticoagulant therapy and survival in PAH. METHODS: A propensity score-based analysis was conducted using data from the national French Pulmonary Hypertension Registry. The findings were then incorporated into an updated meta-analysis of nationwide data sets. RESULTS: Among the 1,597 patients diagnosed with PAH between 2009 and 2020, a total of 380 received anticoagulants at diagnosis. Median survival was 5.62 years (95% CI: 4.76-6.58) for patients receiving anticoagulants and 5.37 years (95% CI: 4.96-5.82) for those not receiving anticoagulants (HR: 0.997; 95% CI: 0.84-1.18; log-rank test, P = 0.97). Findings were consistent across all PAH subgroups within the registry. The updated meta-analysis yielded similar results, with no statistically significant association between anticoagulant use and survival in the overall PAH population (HR: 0.98; 95% CI: 0.78-1.23), as well as in 2 predefined subgroups: 1) idiopathic/heritable PAH or PAH associated with anorexigens (HR: 0.99; 95% CI: 0.79-1.25); and 2) PAH associated with connective tissue disease (HR: 0.86; 95% CI: 0.52-1.42). CONCLUSIONS: Anticoagulant use in PAH was not associated with overall survival in the nationwide registry. These results were supported by an updated meta-analysis. Randomized controlled trials remain the most reliable approach to definitively assess the therapeutic value of anticoagulation in this population.
引用
- Bertoletti L, Escal J, Boucly A, et al. Association Between Anticoagulant Therapy and Survival in Pulmonary Arterial Hypertension: A Registry Report and Updated Meta-Analysis. J Am Coll Cardiol. 2025. PMID: 40992823. doi:10.1016/j.jacc.2025.07.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。